2016 Vitiligo Treatment Study of Abatacept
2016 Vitiligo Treatment Study of Abatacept- Open-label Pilot Study of Abatacept for the Treatment of Vitiligo
Principal Investigator: Dr. Victor Huang
Brigham and Women’s Hospital Clinical Research Program
221 Longwood Ave. Boston, MA 02115
Abatacept has been shown to decrease T cell activity and reduce symptoms associated with rheumatoid arthritis. Similar pathways have been shown to be involved in vitiligo.
This study is seeking adult patients with active vitiligo to receive 24 weekly self-administered injections of abatacept, to see if the vitiligo lesions stop spreading, and start to repigment.
A 32 week follow-up visit will be performed to evaluate secondary endpoints as well.
Must be over the age of 18
Must have actively progressive vitiligo (defined as development of new lesions or worsening of existing lesions within the past 6 months) covering at least 5% of body surface area
Subjects receiving treatment at the time of screening will be eligible providing they undergo a wash out period prior to starting the study
Women of childbearing potential (WOCBP) must be using an acceptable method of contraception throughout the study and for up to 10 weeks after the last dose of study drug, and have a negative serum or urine pregnancy test result (minimum sensitivity 25 IU/L or equivalent units of HCG) within 0 to 48 hours before the first dose of study drug
Sexually active fertile men must use effective birth control if their partners are WOCBP
- Pregnant or breastfeeding patients
- Patients with segmental, acrofacial, or universal vitiligo
- Patients with evidence of white hairs within the majority (>50%) of their vitiligo lesions
- Patients currently on any other systemic biologic medication, current use of Abatacept, or any other systemic biologic medication within 2 months of study
- Use of systemic immunosuppressive agent within 2 weeks prior to initiation of Abatacept
Hayley Pomeroy at 617-525-6823 or email@example.com